Clinical trial
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
NCT05453825
Study timeline
Study start (actual)2022-08-05Date precision: day
Registry last updated2023-01-31
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Colorectal Cancerunresolved
Triple Negative Breast Cancerunresolved
Gastric Cancerunresolved
Ovarian Cancerunresolved
Interventions
navicixizumab+paclitaxelBIOLOGICAL
navicixizumab+irinotecanBIOLOGICAL
navicixizumab monotherapyBIOLOGICAL
Sponsors & collaborators
OncXerna Theraputics, Inc.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05453825 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.